Table 4. Observed Toxicities by Treatment Arm (Randomized Population) and in the Crossover Treatment Population.

Observed Toxicities by Treatment Arm (Randomized Population)	Docetaxel (N=64) Grade						Docetaxel + Vandetanib (N=61) Grade
	1	2	3	4	5	1	2	3	4	5
Hematologic
Anemia	29	16	1	0	0	17	9	2	0	0
Febrile neutropenia	0	0	0	0	0	0	0	1	0	0
Leukocytosis	0	0	0	1	0	0	0	1	0	0
Neutrophil count decreased	0	3	17	15	0	0	3	8	20	0
Platelet count decreased	6	0	0	0	0	5	2	1	0	0
White blood cell decreased	4	10	17	3	0	2	4	17	3	0
Non-Hematologic
Allergic reaction	1	2	0	0	0	0	0	1	0	0
Alopecia	12	31	0	0	0	5	27	0	0	0
Anorexia	5	10	1	0	0	10	5	2	0	0
Constipation	15	7	0	0	0	10	4	1	0	0
ECG QT corrected interval prolonged	0	0	0	0	0	0	2	0	0	0
Edema	9	2	1	0	0	2	3	0	0	0
Elevated Liver Function Tests	8	0	0	0	0	13	0	0	0	0
Fatigue/Malaise	25	17	6	0	0	12	19	5	0	0
Hand-Foot syndrome	4	4	1	0	0	2	0	0	0	0
Hypertension	0	0	0	0	0	1	7	0	0	0
Hypocalcemia	4	1	2	0	0	6	3	0	1	0
Hypokalemia	8	0	1	0	0	2	0	1	0	0
Hypomagnesemia	11	3	0	1	0	19	2	1	1	0
Mucositis oral	15	5	0	1	0	8	9	1	0	0
Myalgia	3	7	0	0	0	10	4	0	0	0
Nail disorders	14	4	0	0	0	9	1	1	0	0
Nausea/Vomiting	22	7	5	0	0	19	8	3	0	0
Neuropathy	25	5	3	0	0	19	0	0	0	0
Proteinuria	3	0	0	0	0	0	0	0	0	0
Rash	8	3	0	0	0	13	11	6	0	0
Thromboembolic event	0	0	0	0	0	0	0	1	0	0
Treatment-related secondary malignancy	0	0	0	0	0	0	0	0	0	1

Observed Toxicities during Crossover Treatment with Vandetanib	Vandetanib (N=33) Grade
	1	2	3	4	5
Hematologic
Anemia	9	2	0	0	0
Neutrophil count decreased	1	0	0	0	0
White blood cell decreased	2	0	0	0	0
Non-Hematologic
Alopecia	2	6	0	0	0
Anorexia	2	1	1	0	0
Constipation	5	4	0	0	0
Elevated Liver Function Tests	5	1	0	0	0
Fatigue/Malaise	11	5	1	0	0
Hand-Foot syndrome	1	1	0	0	0
Hypertension	1	0	2	0	0
Hypokalemia	1	0	0	1	0
Hypomagnesemia	5	1	0	0	0
Mucositis oral	0	1	0	0	0
Myalgia	4	1	1	0	0
Nail disorders	2	0	0	0	0
Nausea/Vomiting	5	1	1	0	0
Neuropathy	8	0	0	0	0
Proteinuria	1	0	0	0	0
Rash	0	1	0	0	0